ICR Expands into Asia Pacific with PACRA
The Institute of Clinical Research (ICR) has signed a significant new partnership agreement to provide research and training to clinical research professionals throughout the Asia Pacific region.
The collaboration with the Pan-Asian Clinical Research Association (PACRA) will expand the ICR’s global presence in the Far East and add new training resources to PACRA members.
Dr Paul Wathall, interim chief executive of the ICR, commented: "We're delighted to be working with PACRA on such an exciting project. ”
PACRA was established earlier this year and aims to promote clinical research training and continuing professional development for clinical researchers in Asia. It provides current information, news and topical articles along with a range of special features for clinical research professionals across the region.
As part of the agreement the ICR’s members’ journal CRfocus will be produced quarterly and rebranded as ‘Silk Route’ for the Asia Pacific members via the PACRA website. Joint members will benefit from discounted ICR learning resources and training courses.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
